Search

everythinglearnresearchcommunity

for

Search:↓

Hair loss discussion includes Minoxidil, finasteride, and RU58841 treatments. Hope Medicine has a new CEO, possibly leading to HMI's termination.

User hoodoomoovoo discusses their interest in stem cell research and its potential for hair loss treatment. They share links to studies and mention ongoing trials, expressing optimism for a future solution to hair loss.

A European individual planning to go to China is seeking information on how to participate in HMI-115 trials for Androgenetic Alopecia. They've tried contacting Mrs. Yang and Mr. Wang for assistance but haven't received a response.

The conversation is about frustration over the delay in phase 2 results for a hair loss treatment called GT20029. One user suspects the treatment may have failed.

New potential hair loss treatment uses molecules from hairy moles to stimulate follicle growth. Topical solution requires less frequent application, like Botox injections a few times per year.

New company Amplifica receives $11.8 million for hair loss product development, co-founded by Dr. Maksim Plikus and William Rassman. Users discuss undisclosed product candidates and application methods.

Hair cloning updates, with potential costs ranging from $200,000 to $350,000. Clinical trials may start in 2020, and some hope for cheaper options in Turkey or China.

Anageninc stopping the sale of Pyrilutamide due to a cease and desist order from Kintor, with some speculating that it was either a hoax or subpar product.

Concerns about CosmeRNA safety mechanisms and potential side effects. Discussion includes comparisons to Fluridil and questions about nanoparticle specificity and siRNA stability.

A user with alopecia totalis, borderline universalis, seeks advice on getting into a Xeljanz trial or appealing insurance for coverage. They experienced significant hair regrowth but are now seeing hair loss again and want to try Xeljanz.

The conversation discusses the effects of Pyrilutamide on hair growth after two months, with one person noting that while new hair regrowth isn't apparent, existing hair appears longer and thicker.

The progress of Phase I of HMI-115, a potential hair loss treatment, which consists of Minoxidil, finasteride, and RU58841. The estimated completion date is June.

A 21-year-old male experienced side effects from topical finasteride and is seeking alternative treatments to maintain hair until Breezula is available. He is considering using minoxidil, Nizoral, micro-needling, and vitamin D supplementation, and may try CB or RU58841 if necessary.

A user confirmed that koshinemall.com is the official site for buying Pyrilutamide after contacting Kintor directly. They expressed initial skepticism due to the website's quality and phone number requirement.

The conversation is about skepticism towards the hair loss treatments RU58841 and Pyrilutamide, with users discussing the lack of human testing for RU58841 and the ongoing trials for Pyrilutamide. Some users believe RU58841 has more anecdotal success, while others highlight Pyrilutamide's current research progress.

The user is hesitant to use finasteride due to potential hormonal side effects and is waiting for the release of pyrilutamide, a new hair loss treatment. Other users suggest trying finasteride, warning about potential regret if hair loss progresses in the meantime.

The conversation is about the release of a new phase 3 clinical trial for a year and questioning if the results of the 6-month clinical trials will be shown this quarter. The specific treatment discussed is Pyrilutamide.

User on 5th week of Pyrilutamide and oral Minoxidil, no hair loss improvement yet. Others suggest waiting 3 months for results.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Update on HMI-115 clinical trial expected in July or August.

Eirion Therapeutics is recruiting for phase 1 of ET-02 in Texas, which showed promising hair growth results in non-clinical studies. ET-02 demonstrated significantly more hair growth compared to Minoxidil.

Follicum discovered that their drug FOL-005 increased hair count by 12 hairs per cm2 in patients with less than 255 hairs per cm2 and is planning a phase 2b trial. They are currently fundraising for the trial, and the drug may also be effective for women.

A user discusses switching from RU58841 to Pyrilutamide due to side effects like fatigue, brain fog, and elevated heart rate. They have used dutasteride, finasteride, and minoxidil, and are seeking safer alternatives.

The discussion is about a hair loss drug called pyrilutamide. Users discuss its efficacy, safety, and expected market release around 2025-2026, with some expressing concerns about the authenticity of current market offerings.

An update on the use of Pyrilutamide, a new drug for hair loss, which has resulted in no shedding or testicle ache; other users have questioned the science behind this and shared their own experiences with Finasteride, Minoxidil, and microneedling.

The post discusses speeding up verteporfin trials for hair loss treatment. The original poster, involved in the trials, requests help in crowdsourcing doctor emails to spread awareness and gather more support for the trials.

A user applied pyrilutamide for 6 months without hair regrowth and is considering stopping due to cost and lack of results. Another user suggests switching to finasteride, which is cheaper and has shown regrowth for them.

The conversation is about the progress of clinical trials for SCUBE3, a potential hair loss treatment. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

The conversation is about a user seeking information on a clinical trial by Amplifica - Scube3 for Androgenetic Alopecia (AGA). The user is unsure if it's a formal phase 1 study.

The conversation is about the release timeline for clinical trial results and the availability of Breezula, a hair loss treatment. The user is not comfortable buying it as a research drug from China.

User discusses potential hair loss cure involving growth factors from a hairy mole. Dr. Wrassman responds, saying clinical trials may happen in 2022.